- Shanghai Jizhi Biochemical Technology Co., Ltd
- China
- Product Name: Serabelisib
- Price: ￥876.0/5mg ￥5356.0/100mg ￥3406.0/50mg ￥1166.0/10mg
- Purity: 98.0%
- Stocking Period: 2 Day
- Contact: Liu jia
- DC Chemicals Limited
- China
- Product Name: Serabelisib(TAK-117,INK1117,MLN1117)
- Price: $500.0/100mg $900.0/250mg $1800.0/1g
- Purity: 98.0%
- Stocking Period: 3 Day
- Contact: Tony Cao
1268454-23-4
1268454-23-4 structure
- Name: Serabelisib
- Chemical Name: [6-(2-amino-1,3-benzoxazol-5-yl)imidazo[1,2-a]pyridin-3-yl]-morpholin-4-ylmethanone
- CAS Number: 1268454-23-4
- Molecular Formula: C19H17N5O3
- Molecular Weight: 363.37000
- Catalog: Research Areas Cancer
- Create Date: 2018-08-30 09:32:20
- Modify Date: 2024-01-29 15:42:59
-
Serabelisib (MLN1117) is a selective p110α inhibitor with an IC50 of 15 nM.
| Name | [6-(2-amino-1,3-benzoxazol-5-yl)imidazo[1,2-a]pyridin-3-yl]-morpholin-4-ylmethanone |
|---|---|
| Synonyms |
UNII-43J9Q56T3W
[6-(2-amino-4,6,7-trideuterio-1,3-benzoxazol-5-yl)imidazo[1,2-a]pyridin-3-yl]-morpholin-4-ylmethanone INK 1117 INK-1117 Methanone, [6-(2-amino-5-benzoxazolyl)imidazo[1,2-a]pyridin-3-yl]-4-morpholinyl- [6-(2-Amino-1,3-benzoxazol-5-yl)imidazo[1,2-a]pyridin-3-yl](4-morpholinyl)methanone serabelisib MLN 1117 TAK-117 MLN1117 |
| Description | Serabelisib (MLN1117) is a selective p110α inhibitor with an IC50 of 15 nM. |
|---|---|
| Related Catalog | |
| Target |
p110α:15 nM (IC50) p110β:4500 nM (IC50) p110δ:13900 nM (IC50) p110γ:1900 nM (IC50) mTOR:1670 nM (IC50) |
| In Vitro | Serabelisib (MLN1117) inhibits Akt phosphorylation and growth in PIK3CA mutant breast cancer cells with IC50s around 2 μM, yet has no effect on cells lacking PTEN. BCR-stimulated B cells treated with 1 μM Serabelisib (MLN1117) displays a significant reduction (up to 50%) in the magnitude of the phosphorylated Akt (p-Akt) signal measured by intracellular flow cytometry. The effect of Serabelisib is dose-dependent[1]. |
| In Vivo | Treatment with Serabelisib (MLN1117) at 30 and 60 mg/kg causes little reduction of TNP-specific IgG3. Notably, reduction of TNP-specific IgG3 at higher doses of Serabelisib (MLN1117) (120 mg/kg) is observed, consistent with the partial reduction in cell division in B cells treated with Serabelisib before anti-IgM stimulation. However, 120 mg/kg is above the effective dose of Serabelisib (MLN1117) for tumor growth inhibition (30-60 mg/kg)[1]. |
| Cell Assay | A total of 5000 SK-OV-3 and U87MG cell lines/well in low serum media (0.2% FBS) are seeded in triplicate wells of a 96-well flat bottom culture plate for 18 h to adhere. Media is aspirated and inhibitors in 0.2% FBS media are added to each well at the indicated concentrations. After 48 h, cell viability is determined using the MTS assay (Cell Titer 96 Aqueous One solution cell proliferation assay kit) with absorbance (490 nm) measured in a microplate spectrophotometer[1]. |
| Animal Admin | Mice[1] Wild-type 8-week-old Balb/cJ mice are used for all experiments. Serabelisib and GDC-0941 are given by oral gavage using a sterile disposable 20-guage 1.5′ feeding needle. IC87114 is delivered via intraperitoneal injection. For the non-immunization experiment, 2 mice per group (Vehicle, GDC-0941, and Serabelisib (MLN1117)) are given the indicated drugs for 9 days before sacrificing on day 10. For the immunization experiment, 4 mice per group are used to perform two independent studies comparing GDC-0941 or IC87114 to Serabelisib (MLN1117). In all cases, the vehicle group receive both vehicles used to formulate the two different drugs. Mice are treated with the drugs throughout day -1 to day 13. On day 0, all mice are immunized with NP-OVA precipitated in alum. Drug treatment is stopped on day 13 and mice are sacrificed for collection of serum and spleens. |
| References |
| Density | 1.6±0.1 g/cm3 |
|---|---|
| Molecular Formula | C19H17N5O3 |
| Molecular Weight | 363.37000 |
| Exact Mass | 363.13300 |
| PSA | 99.62000 |
| LogP | 1.40 |
| Index of Refraction | 1.768 |
| Storage condition | -20℃ |